You are here

  • Home
  • Online First
  • Current 10-year atherosclerotic cardiovascular disease risk threshold for statin eligibility is cost-effective for primary prevention

Article Text

Article menu

other Versions

Download PDFPDF
Economic analysis
Cost-effectiveness
Current 10-year atherosclerotic cardiovascular disease risk threshold for statin eligibility is cost-effective for primary prevention
  1. Joseph Yeboah
  1. Wake Forest School of Medicine, Winston-Salem, USA
  1. Correspondence to : Dr Joseph Yeboah, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem NC 27157, USA; jyeboah{at}wakehealth.edu

https://doi.org/10.1136/ebmed-2015-110277

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Pandya A, Sy S, Cho S, et al. Cost effectiveness of 10-year risk thresholds for initiation of statin therapy for primary prevention of cardiovascular disease. JAMA 2015;314:142–50.OpenUrlCrossRefPubMed

    Context

    The American College of Cardiology American Heart Association (ACC/AHA) cholesterol guidelines replaced the National Cholesterol Education Program Adult Treatment Panel III (NCEP/ATP III) in 2013,1 a change that was accompanied by significant controversy.2 Notable among the criticisms was that the pooled cohort equations (PCE) overestimates risk and coupled with the relatively lenient risk threshold (10-year PCE ≥7.5%), would unnecessarily increase statin eligibility in the USA. The risk-benefit ratio and cost-effectiveness of this new approach, specifically for primary prevention, was questioned since statins (in addition to preventing cardiovascular disease (CVD) events) have known significant side effects. Pandya and colleagues examine the cost-effectiveness of 10-year risk thresholds for initiation …

    View Full Text

    Footnotes

    • Competing interests None declared.

    • Provenance and peer review Commissioned; internally peer reviewed.